April 17 (Reuters) - The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand. (Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
771.6 USD | -0.45% | +2.07% | +32.36% |
May. 08 | China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target | MT |
May. 07 | Coca Cola's new bond prices tight, investors still hungry for new debt | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B | |
-2.12% | 160B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Most doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says